Jefferies Financial Group Analysts Reduce Earnings Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Jefferies Financial Group decreased their FY2021 earnings per share estimates for Halozyme Therapeutics in a research report issued on Monday, January 10th. Jefferies Financial Group analyst E. Yang now expects that the biopharmaceutical company will post earnings per share of $1.80 for the year, down from their prior estimate of $1.86. Jefferies Financial Group also issued estimates for Halozyme Therapeutics’ Q1 2022 earnings at $0.41 EPS, Q2 2022 earnings at $0.51 EPS, Q3 2022 earnings at $0.57 EPS, Q4 2022 earnings at $0.48 EPS, FY2022 earnings at $1.97 EPS and FY2023 earnings at $3.18 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $1.06. Halozyme Therapeutics had a return on equity of 187.85% and a net margin of 88.36%. The business had revenue of $115.83 million for the quarter, compared to analyst estimates of $101.94 million. During the same quarter last year, the firm earned $0.25 EPS.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Halozyme Therapeutics from a “hold” rating to a “strong sell” rating and set a $30.00 target price on the stock. in a research report on Thursday. raised their price target on Halozyme Therapeutics from $27.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, December 2nd. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $60.00 to $58.00 and set an “overweight” rating for the company in a research note on Wednesday, November 24th. SVB Leerink decreased their price target on Halozyme Therapeutics from $50.00 to $48.00 and set an “outperform” rating for the company in a research note on Wednesday, November 3rd. Finally, TheStreet upgraded Halozyme Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, September 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $51.25.

Shares of Halozyme Therapeutics stock opened at $35.56 on Thursday. The business’s 50 day simple moving average is $36.70 and its 200 day simple moving average is $39.60. Halozyme Therapeutics has a 52-week low of $31.79 and a 52-week high of $56.40. The firm has a market cap of $5.01 billion, a PE ratio of 12.75 and a beta of 1.30. The company has a debt-to-equity ratio of 2.79, a quick ratio of 8.50 and a current ratio of 8.99.

In other news, CEO Helen Torley sold 50,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, November 8th. The stock was sold at an average price of $39.82, for a total transaction of $1,991,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Connie Matsui sold 32,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Friday, November 5th. The stock was sold at an average price of $40.38, for a total value of $1,292,160.00. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Synovus Financial Corp lifted its holdings in Halozyme Therapeutics by 19.9% during the 3rd quarter. Synovus Financial Corp now owns 61,400 shares of the biopharmaceutical company’s stock worth $2,495,000 after purchasing an additional 10,181 shares during the last quarter. Swiss National Bank lifted its holdings in Halozyme Therapeutics by 5.5% during the 3rd quarter. Swiss National Bank now owns 298,900 shares of the biopharmaceutical company’s stock worth $12,159,000 after purchasing an additional 15,600 shares during the last quarter. Amundi acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $335,000. New York State Common Retirement Fund lifted its holdings in Halozyme Therapeutics by 8.3% during the 3rd quarter. New York State Common Retirement Fund now owns 1,749,309 shares of the biopharmaceutical company’s stock worth $71,162,000 after purchasing an additional 133,986 shares during the last quarter. Finally, Securian Asset Management Inc lifted its holdings in Halozyme Therapeutics by 3.0% during the 2nd quarter. Securian Asset Management Inc now owns 12,300 shares of the biopharmaceutical company’s stock worth $559,000 after purchasing an additional 355 shares during the last quarter. 90.56% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Story: How do investors use RSI to grade stocks?

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.